Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and PK Comparison of Bardoxolone Methyl in Healthy Adults
NCT04023903Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Apr 2019
- Primary completion
- Jun 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bardoxolone methyl in diabetic kidney disease (DKD) and Alport syndrome (2 arms), sponsored by Kyowa Kirin. Primary endpoints: Maximum Plasma Concentration at 96 hours and Area Under the Curve to last quantifiable time at 96 hours. Started Apr 2019; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
diabetic kidney disease (DKD)Alport syndrome
Beyond the preview
Go deeper on NCT04023903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04023903.